Mode
Text Size
Log in / Sign up
N/A N=163 Other

Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

Enrolled (actual)
163
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Time to Resolution of Metabolic Acidosis — 12.84; 12.02 hours

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
DEXCOM G6 CGM (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Columbia University
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Resolution of Metabolic Acidosis
12.84; 12.02
SECONDARY
Length of ICU Stay
28.47
SECONDARY
Length of Hospital Stay
120; 99.08
SECONDARY
Number of Hypoglycemic Events
0; 3

Summary

The purpose of this research study is to investigate the use of continuous glucose monitoring (CGM) device DEXCOM G6 in non-critically patients treated for diabetic emergency such as diabetic ketoacidosis (DKA). Patients who have DKA require hourly monitoring of glucose (sugar) level which traditionally requires admission to the intensive care unit (ICU) for hourly fingerstick monitoring. With the use of CGM device, in this research study hourly fingerstick monitoring is replaced by continuous glucose monitor (CGM) which provides glucose levels continuously in real time for nurses and provider. The investigators are testing to see if in the future patients can be treated in the stepdown unit (an intermediate care level between the intensive care unit and the general medical unit) if they do not require higher level of care besides hourly glucose monitoring. Continuous glucose monitoring (CGM) device DEXCOM G6 currently FDA Approved for patients with diabetes and is widely used for glucose monitoring in patients with diabetes in the outpatient setting. The investigators want to study the use of the DEXCOM G6 CGM in the inpatient setting to monitoring glucose levels remotely in the treatment of diabetic emergencies such as diabetic ketoacidosis and compare their care to those receiving hourly fingerstick glucose monitoring in the ICU.

Eligibility Criteria

Inclusion Criteria

  • Age >18 years
  • AG>20 mEq/L
  • Bicarbonate 0.3 mmol/L

Exclusion Criteria

  • Hypotension (Blood Pressure below 80/60 mmHg)
  • Requirement for pressor therapy
  • Contraindication for utilizing Dexcom CGM
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05439928). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search